Home
Resources
Publications
Evidence for Improvement in Survival With Antihypertensive Combination Treatment

Evidence for Improvement in Survival With Antihypertensive Combination Treatment

Frank Ruschitzka

J Hypertens. 2011 Dec;29 Suppl 1:S9-14.

PMID: 22157566

Abstract:

Hypertension constitutes a major risk factor for an array of cardiovascular diseases. Rates of morbidity and mortality related to its complications are high and remain an important concern in terms of public health. Improvement in cardiovascular outcomes and survival is an ultimate goal of the antihypertensive treatment. However, despite the wide range of available antihypertensive drugs, the rates of BP control are still insufficient. In most hypertensive patients, more than one antihypertensive compound is necessary to achieve goal levels of blood pressure. Assuming a greater antihypertensive effect may be obtained from two or more agents given in association, many combination therapies have been proposed and tested in a number of studies. The best clinical trial evidence comes from large outcome studies with an ACE inhibitor and dihydropyridine calcium antagonist combination, that of perindopril/amlodipine in the ASCOT trial in particular.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
ALP113994415	Amlodipine Related Compound A		113994-41-5 (free base)	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: